【瑞博生物-B:核心产品VORTOSIRAN针对SPAF的2B期临床试验获EMA批准】瑞博生物-B公告,欧洲药品管理局已批准启动评估vortosiran 的2b期临床试验ORBIT-XI-AF,用于心房颤动患者的中风预防,该疗法为全球首创且开发进度最为领先的靶向XI凝血因子的小干扰核酸疗法。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.